Corvas completes Phase IIb stroke enrollment

CVAS partner Pfizer (PFE) completed enrollment in a Phase IIb trial of UK-279,276 (formerly neutrophil inhibitory factor), to treat ischemic stroke. The goal of the study is to determine the dose-rela...